Abbvie Inc (ABBV)

$250.94 -6.47 (-2.51%)
Market Cap 443.36B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 25.26
Forward PE 18.20
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 7,258,100
Avg Vol 7,045,918
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 19%
Beta 0.30
Analysts Strong Sell
Price Target $265.79

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 2 at 10:27 PM
$SLS @Stochasty // interestingly, in all the published trial data, for Aml and R/R AML - there is always a statement - that transplant remains the only curative treatment, and absent transplant survival is not durable... BAT . . . is a misnomer. BAT - should be referred to as, 'the only treatment available', -- Aza+VEN in VIALE-A was approved, only because these AML Newly diagnosed patients, were unable to Handle/survive Induction Chemo, 7+3 the SOC was death. Having no treatment was also death - so Aza+VEN in the VIALE-A trial - worked, for Some, likely the strongest, but it is not close to an effective maintenance therapy. -• Aza+VEN Killed 23% of the VIALE - A Patients and Subsequently FAILED 3 Large Phase 3 Trials conducted by $ABBV $BMY VIALE-M AML Phase 3 for First Remission Maintenance Failed --- it is not working for the AML Second Remissioin Patients in the SLS p3 Either. $XBI
1 · Reply
RunnerSignals
RunnerSignals Aug. 2 at 5:08 PM
$NUVB $ABBV $VRTX $NVS trade below consensus targets while holding key averages. the market may be underpricing catalysts, not deterioration https://stocksrunner.com/news/2026-08-02-value-repricing-candidates-with-technical-support
0 · Reply
Tom2772
Tom2772 Aug. 2 at 4:57 PM
$OTLK $REGN $ABBV Wake up! If you haven't read the brand-new Corporate Presentation (August 2026) yet, it's worth a look. It includes the company's first published U.S. base-case sales estimate for LYTENAVA, along with several other important updates. https://ir.outlooktherapeutics.com/static-files/0e6b91b1-39aa-43ce-b4d7-356b2da93aac⁠
0 · Reply
Tom2772
Tom2772 Aug. 2 at 7:49 AM
$OTLK $REGN $ABBV Beyond the market opportunity, the new Corporate Presentation places a clear emphasis on commercial execution. It highlights the build-out of the commercial organization, payer engagement, HCPCS code submission, customer targeting, commercial supply, and the continued refinement of its commercialization strategy in response to the evolving biosimilar market. Against that backdrop, the >$500M U.S. base-case estimate becomes more meaningful to me. It's not just a number, it reflects a commercialization strategy designed for execution and supported by an experienced leadership team. Sounds good!
0 · Reply
PredictionFLO1
PredictionFLO1 Aug. 1 at 8:42 PM
Heavy flow on $ABBV: $150K of premium through the Sep 4 $250 puts, 34 days to expiry. The strike sits basically at the money with spot near $250.94, a clean directional bet, delta working from day one. Volume ran 20.3x the standing open interest, which is the signature of a position being built, not unwound. Smaller in size, but a clean one sided print. Caveat that matters: big put buys aren't automatically bearish, funds hedge long books with them all the time. Urgency and strike selection are what separate a hedge from a bet. Not a trade rec, just flow worth having on the radar.
0 · Reply
FlyingChemist01
FlyingChemist01 Aug. 1 at 12:20 PM
$ABBV $MLTX ​"AbbVie has increased its revenue projection for Skyrizi to $21.7 billion for this year, which would top the $21.2 billion high achieved by Humira in 2022, which was its last full year of patent protection in the U.S." ​ Humira is now old news since ​right now, AbbVie's cash cow is Skyrizi, generating far more revenue than even they anticipated. MoonLake's target is to steal market share from both AbbVie's legacy success (Humira) and its current powerhouse, Skyrizi. It will be fascinating to see whether AbbVie lets MoonLake slip into the hands of a competitor or if they step in to lock it down themselves to maintain their dominance in immunology. ​The fact that Skyrizi is racking up record revenue is actually great news for MoonLake: the higher Skyrizi’s revenue grows, the more cash reserves AbbVie builds up to defend that market share.
2 · Reply
DeannaBishop387
DeannaBishop387 Aug. 1 at 12:01 PM
$ABBV AbbVie combines strong pharmaceutical cash flows with an attractive dividend. Growth from newer immunology and neuroscience products is expected to offset legacy product declines.
0 · Reply
wyoming2020
wyoming2020 Aug. 1 at 11:10 AM
$VKTX with 1B in cash expected, a late stage pipeline, seems a very nice setup for a cash and stock merger, low-risk for a buyer here. An $ABBV or $JNJ could pick this up by sneezing
5 · Reply
Tom2772
Tom2772 Aug. 1 at 7:35 AM
$OTLK $REGN $ABBV The brand-new Corporate Presentation (August 2026) strengthens my confidence in $OTLK's future over the next few years. The company is targeting a global Anti-VEGF retina market opportunity of >$15.9B. For the U.S. market, Outlook outlines a base-case of >$500M in annual sales before 2030 for LYTENAVA. Just as important, execution is backed by a leadership team with nearly 200 years of ophthalmology and launch experience, executive experience across 51 companies, and involvement in 15 product launches, including 12 in ophthalmology. Taken together, this presentation highlights what appears to be a compelling opportunity 💎 https://ir.outlooktherapeutics.com/static-files/0e6b91b1-39aa-43ce-b4d7-356b2da93aac
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 1 at 6:23 AM
$SLS @wwmeinc is either an idiot or a short idiot liar. The IDMC UNBLINDED ACTUAL PHASE 3 MOS AND IMMUNE RESPONSE DATA FROM THE INTERIM ANALYSIS. SINCE THEN: SLS SHARE PRICE +1,000% Market Cap+1,200%, Cash on hand Up 1,100% Institutional Funds Up 800% Smart Money Knows Dr’s treating actual patients, know. $ABBV knows - VIALE-M VIALE-T VERONA Failed idiots like wwmeinc don’t have a clue.
0 · Reply
Latest News on ABBV
AbbVie says ‘quite pleased’ with Skyrizi momentum

2026-07-31T14:01:14.000Z - 2 days ago

AbbVie says ‘quite pleased’ with Skyrizi momentum

AbbVie raises FY26 revenue view to about $67.6B from about $67.3B

2026-07-31T13:31:24.000Z - 2 days ago

AbbVie raises FY26 revenue view to about $67.6B from about $67.3B

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

2026-07-31T13:30:48.000Z - 2 days ago

AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

2026-07-31T13:30:35.000Z - 2 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

AbbVie says continues to make ‘excellent progress’ advancing pipeline

2026-07-31T13:16:13.000Z - 2 days ago

AbbVie says continues to make ‘excellent progress’ advancing pipeline

AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 2 days ago

AbbVie Earnings Call Transcript: Q2 2026

AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 2 days ago

AbbVie Earnings release: Q2 2026

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

Jul 31, 2026, 8:36 AM EDT - 2 days ago

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

Jul 31, 2026, 8:31 AM EDT - 2 days ago

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

AbbVie reports Q2 adjusted EPS $3.65, consensus $3.61

2026-07-31T11:51:57.000Z - 2 days ago

AbbVie reports Q2 adjusted EPS $3.65, consensus $3.61

AbbVie cuts FY26 adjusted EPS view to $13.87-$14.07 from $13.91-$14.11

2026-07-31T11:50:17.000Z - 2 days ago

AbbVie cuts FY26 adjusted EPS view to $13.87-$14.07 from $13.91-$14.11

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

Jul 31, 2026, 7:50 AM EDT - 2 days ago

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 2 days ago

AbbVie Reports Second-Quarter 2026 Financial Results

JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 3 days ago

JUVÉDERM® Day Returns to U.S. on August 19

AbbVie announces Elahere availability in Singapore

2026-07-29T09:30:43.000Z - 4 days ago

AbbVie announces Elahere availability in Singapore

AbbVie announces European Commission approval for Rinvoq

2026-07-29T09:15:30.000Z - 4 days ago

AbbVie announces European Commission approval for Rinvoq

AbbVie price target raised to $300 from $275 at Barclays

2026-07-29T09:10:59.000Z - 4 days ago

AbbVie price target raised to $300 from $275 at Barclays

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jul 29, 2026, 3:00 AM EDT - 4 days ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Jul 29, 2026, 3:00 AM EDT - 4 days ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial

2026-07-23T20:05:43.000Z - 10 days ago

Genmab, AbbVie provide clarification on Phase 3 EPCORE(R) DLBCL-1 trial

GMAB

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jul 23, 2026, 4:00 PM EDT - 10 days ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GMAB

AbbVie price target raised to $282 from $273 at Canaccord

2026-07-22T10:40:12.000Z - 11 days ago

AbbVie price target raised to $282 from $273 at Canaccord

AbbVie’s Allergan Aesthetics receives approval for Boey in Europe

2026-07-17T12:05:34.000Z - 16 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Europe

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jul 17, 2026, 8:00 AM EDT - 16 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie price target raised to $260 from $230 at Citi

2026-07-15T10:21:06.000Z - 18 days ago

AbbVie price target raised to $260 from $230 at Citi

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Jul 14, 2026, 8:05 AM EDT - 19 days ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Jul 13, 2026, 5:06 PM EDT - 20 days ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

APGE SBIO

AbbVie price target raised to $260 from $230 at UBS

2026-07-13T16:30:09.000Z - 20 days ago

AbbVie price target raised to $260 from $230 at UBS

AbbVie price target raised to $300 from $258 at BMO Capital

2026-07-13T12:27:09.000Z - 20 days ago

AbbVie price target raised to $300 from $258 at BMO Capital

Buy these quality, low-stress stocks for the summer, says Jefferies

Jul 7, 2026, 11:45 AM EDT - 26 days ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jul 6, 2026, 1:45 PM EDT - 27 days ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 4 weeks ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 4:15 PM EDT - 4 weeks ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:10 AM EDT - 4 weeks ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 29, 2026, 3:00 AM EDT - 4 weeks ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 5 weeks ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 5 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 5 weeks ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 5 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 5 weeks ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 5 weeks ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 5 weeks ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 5 weeks ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 5 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Press release: M&A announcement

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 5 weeks ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 5 weeks ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 5 weeks ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 5 weeks ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 6 weeks ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 6 weeks ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 6 weeks ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 6 weeks ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 7 weeks ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 7 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 10, 2026, 11:47 AM EDT - 7 weeks ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:40 AM EDT - 7 weeks ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 2 months ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 2 months ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 2 months ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 2 months ago

US FDA approves AbbVie's rare blood cancer drug

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 2 months ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 2 months ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 2 months ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 3 months ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 3 months ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 2 at 10:27 PM
$SLS @Stochasty // interestingly, in all the published trial data, for Aml and R/R AML - there is always a statement - that transplant remains the only curative treatment, and absent transplant survival is not durable... BAT . . . is a misnomer. BAT - should be referred to as, 'the only treatment available', -- Aza+VEN in VIALE-A was approved, only because these AML Newly diagnosed patients, were unable to Handle/survive Induction Chemo, 7+3 the SOC was death. Having no treatment was also death - so Aza+VEN in the VIALE-A trial - worked, for Some, likely the strongest, but it is not close to an effective maintenance therapy. -• Aza+VEN Killed 23% of the VIALE - A Patients and Subsequently FAILED 3 Large Phase 3 Trials conducted by $ABBV $BMY VIALE-M AML Phase 3 for First Remission Maintenance Failed --- it is not working for the AML Second Remissioin Patients in the SLS p3 Either. $XBI
1 · Reply
RunnerSignals
RunnerSignals Aug. 2 at 5:08 PM
$NUVB $ABBV $VRTX $NVS trade below consensus targets while holding key averages. the market may be underpricing catalysts, not deterioration https://stocksrunner.com/news/2026-08-02-value-repricing-candidates-with-technical-support
0 · Reply
Tom2772
Tom2772 Aug. 2 at 4:57 PM
$OTLK $REGN $ABBV Wake up! If you haven't read the brand-new Corporate Presentation (August 2026) yet, it's worth a look. It includes the company's first published U.S. base-case sales estimate for LYTENAVA, along with several other important updates. https://ir.outlooktherapeutics.com/static-files/0e6b91b1-39aa-43ce-b4d7-356b2da93aac⁠
0 · Reply
Tom2772
Tom2772 Aug. 2 at 7:49 AM
$OTLK $REGN $ABBV Beyond the market opportunity, the new Corporate Presentation places a clear emphasis on commercial execution. It highlights the build-out of the commercial organization, payer engagement, HCPCS code submission, customer targeting, commercial supply, and the continued refinement of its commercialization strategy in response to the evolving biosimilar market. Against that backdrop, the >$500M U.S. base-case estimate becomes more meaningful to me. It's not just a number, it reflects a commercialization strategy designed for execution and supported by an experienced leadership team. Sounds good!
0 · Reply
PredictionFLO1
PredictionFLO1 Aug. 1 at 8:42 PM
Heavy flow on $ABBV: $150K of premium through the Sep 4 $250 puts, 34 days to expiry. The strike sits basically at the money with spot near $250.94, a clean directional bet, delta working from day one. Volume ran 20.3x the standing open interest, which is the signature of a position being built, not unwound. Smaller in size, but a clean one sided print. Caveat that matters: big put buys aren't automatically bearish, funds hedge long books with them all the time. Urgency and strike selection are what separate a hedge from a bet. Not a trade rec, just flow worth having on the radar.
0 · Reply
FlyingChemist01
FlyingChemist01 Aug. 1 at 12:20 PM
$ABBV $MLTX ​"AbbVie has increased its revenue projection for Skyrizi to $21.7 billion for this year, which would top the $21.2 billion high achieved by Humira in 2022, which was its last full year of patent protection in the U.S." ​ Humira is now old news since ​right now, AbbVie's cash cow is Skyrizi, generating far more revenue than even they anticipated. MoonLake's target is to steal market share from both AbbVie's legacy success (Humira) and its current powerhouse, Skyrizi. It will be fascinating to see whether AbbVie lets MoonLake slip into the hands of a competitor or if they step in to lock it down themselves to maintain their dominance in immunology. ​The fact that Skyrizi is racking up record revenue is actually great news for MoonLake: the higher Skyrizi’s revenue grows, the more cash reserves AbbVie builds up to defend that market share.
2 · Reply
DeannaBishop387
DeannaBishop387 Aug. 1 at 12:01 PM
$ABBV AbbVie combines strong pharmaceutical cash flows with an attractive dividend. Growth from newer immunology and neuroscience products is expected to offset legacy product declines.
0 · Reply
wyoming2020
wyoming2020 Aug. 1 at 11:10 AM
$VKTX with 1B in cash expected, a late stage pipeline, seems a very nice setup for a cash and stock merger, low-risk for a buyer here. An $ABBV or $JNJ could pick this up by sneezing
5 · Reply
Tom2772
Tom2772 Aug. 1 at 7:35 AM
$OTLK $REGN $ABBV The brand-new Corporate Presentation (August 2026) strengthens my confidence in $OTLK's future over the next few years. The company is targeting a global Anti-VEGF retina market opportunity of >$15.9B. For the U.S. market, Outlook outlines a base-case of >$500M in annual sales before 2030 for LYTENAVA. Just as important, execution is backed by a leadership team with nearly 200 years of ophthalmology and launch experience, executive experience across 51 companies, and involvement in 15 product launches, including 12 in ophthalmology. Taken together, this presentation highlights what appears to be a compelling opportunity 💎 https://ir.outlooktherapeutics.com/static-files/0e6b91b1-39aa-43ce-b4d7-356b2da93aac
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 1 at 6:23 AM
$SLS @wwmeinc is either an idiot or a short idiot liar. The IDMC UNBLINDED ACTUAL PHASE 3 MOS AND IMMUNE RESPONSE DATA FROM THE INTERIM ANALYSIS. SINCE THEN: SLS SHARE PRICE +1,000% Market Cap+1,200%, Cash on hand Up 1,100% Institutional Funds Up 800% Smart Money Knows Dr’s treating actual patients, know. $ABBV knows - VIALE-M VIALE-T VERONA Failed idiots like wwmeinc don’t have a clue.
0 · Reply
RayWashburn860
RayWashburn860 Aug. 1 at 5:10 AM
$ABBV AbbVie combines stable pharmaceutical cash flows with an attractive dividend profile. New immunology and neuroscience products are expected to offset declining Humira revenue over the coming years.
0 · Reply
BioTechHealthX
BioTechHealthX Aug. 1 at 3:55 AM
$ABBV Humira sales plunged nearly 39%, but AbbVie’s revenue and earnings continued climbing as Skyrizi and Rinvoq delivered blockbuster growth. Here is why ABBV stock’s comeback story is turning heads. https://biotechhealthx.com/biotech-news/is-abbvie-abbv-a-smart-dividend-stock-to-buy-now/
0 · Reply
Wstb100
Wstb100 Jul. 31 at 11:17 PM
$ABBV closed my short. Enough to eat for free at a Jimmy Buffet restaurant for a table of 9. Back to my long position.
1 · Reply
ItTakes2toContango
ItTakes2toContango Jul. 31 at 5:29 PM
$ABBV Sold at $260 before ER simply because I won’t hold anything through ER in this environment. Price seems to have stabilized at ~$250 and I have bought back my shares. Looking for $270 by next ER.
1 · Reply
DidYouReadThis
DidYouReadThis Jul. 31 at 4:40 PM
$NVS $ALGN $ABBV $IHF
1 · Reply
katiemcdaniels96
katiemcdaniels96 Jul. 31 at 3:01 PM
$ABBV AbbVie Reports Second-Quarter 2026 Financial Results | AbbVie https://share.google/LHV4rygaQs8RTMpXG
0 · Reply
Quantumup
Quantumup Jul. 31 at 2:48 PM
BRiley🏁 $FDMT and said -- We are initiating coverage of retinal genetic medicines specialist 4D Molecular Therapeutics, Inc. (FDMT) with a Buy rating and a 12-month price target of $37/share. OCUL EYPT $RGNX - $ABBV $REGN $RHHBY SRZN KOD OTLK NVS Here's what else BRiley had to say in its initiation report: https://x.com/Quantumup1/status/2083203038202692017?s=20
0 · Reply
EarningsInsider
EarningsInsider Jul. 31 at 2:31 PM
https://www.marketbeat.com/earnings/reports/2026-7-31-abbvie-inc-stock/ $ABBV AbbVie Earnings Transcript
0 · Reply
Social_Idiot
Social_Idiot Jul. 31 at 1:26 PM
$ABBV Over performing and exceeding expectations and projections everywehere.... Makes me think that they're bad at projections.
0 · Reply
msgetzoff
msgetzoff Jul. 31 at 1:22 PM
$ABBV ....blowout numbers and we're down (+)$10 ?? Forget the nonsensical reason of the Apogee acquisition & sales declines from Humira. Humira is old news & already baked in. As for Apogee, this is their business model. Pretty sure they know what 2do.
0 · Reply
profit_guru
profit_guru Jul. 31 at 1:19 PM
$ABBV - competition to skyrizi from $JNJ is big red flag for the high multiple going forward…near term 230..,imo
0 · Reply
crtlabz
crtlabz Jul. 31 at 1:13 PM
$ABBV staying long after 23yrs (original $39K to$3.2M w/periodic dip buying + reinvest).
3 · Reply